GAITHERSBURG, Md., Sept. 30 /PRNewswire-FirstCall/ -- GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the research of a new approach to treating metastatic cancer. Under this grant, valued at over $300,000, GenVec will investigate the hypothesis that the delivery of a specific gene will stimulate an antitumor response that could control cancer metastases.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )
“Funding from this grant provides GenVec with an opportunity to expand our cancer program and explore a novel approach to cancer treatment,” said Dr. Douglas Brough, GenVec’s Executive Director, Head of Research. “The work expected to be conducted under this grant will explore new ways to control metastases, addressing a severely unmet medical need.”
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec’s lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company’s various filings with the Securities and Exchange Commission.
SOURCE GenVec, Inc.
CONTACT: Investor Contact, Danielle M. DiPirro of GenVec, Inc.,
+1-301-944-1877, ddipirro@genvec.com, or Media Contact, Andrew Mielach of
Tiberend Strategic Advisors, Inc. for GenVec, Inc., +1-212-827-0020,
amielach@tiberendstrategicadvisors.com
Web site: http://www.genvec.com/
